Anatara Lifesciences announced that Dr Jane Ryan has retired as Non-Executive Director effective immediately. Mr. John Michailidis has simultaneously been appointed as an Executive Director and remains in the role of COO (Chief Operating Officer). The Board now consists of Dr David Brookes as Executive Chair, Mr. Nick Haslam as Non-Executive Director and Chair of the Audit and Risk Committee, and John Michailidis whose bio follows: John has more than 30 years of pharmaceutical experience.

He is a driven leader in business transformation, entrepreneurship, translation and commercialisation, and has experience and expertise in a broad range of areas including strategic planning, organisational growth and business development. John is currently the Chief Operating Officer of Anatara and the Managing Director of JEM Pharmaceuticals Pty Ltd. He has gained experience in a number of senior and executive positions throughout his career, including as Non-Executive Director of Factor Therapeutics Pty Ltd. and Australian Diabetes Educators Association, the Chair of Access Community Health, Managing Director of Teva Pharma Australia Pty Ltd. and Business Director and Global Head of the Nephrology/Oncology Franchise for F. Hoffman La Roche. John also has CEO experience with growth-stage pharmaceutical companies including Orphan Australia Pty Ltd, Avipep Pty Ltd. and Roche Korea Ltd. John holds a Bachelor of Science (Honours) from LaTrobe University, an Executive MBA from Harvard University, a Diploma in Education from Melbourne University, and he is a member of the Australian Institute of Company Directors.